000284769 001__ 284769
000284769 005__ 20240925143715.0
000284769 0247_ $$2doi$$a10.1097/PRS.0000000000011141
000284769 0247_ $$2pmid$$apmid:37832143
000284769 0247_ $$2ISSN$$a0032-1052
000284769 0247_ $$2ISSN$$a1076-5751
000284769 0247_ $$2ISSN$$a1529-4242
000284769 0247_ $$2ISSN$$a2169-7574
000284769 037__ $$aDKFZ-2023-02080
000284769 041__ $$aEnglish
000284769 082__ $$a610
000284769 1001_ $$aWill, Patrick A$$b0
000284769 245__ $$aLymphedema-Associated Fibroblasts Are Related to Fibrosis and Stage Progression in Patients and a Murine Microsurgical Model
000284769 260__ $$a[Erscheinungsort nicht ermittelbar]$$bOvid$$c2024
000284769 3367_ $$2DRIVER$$aarticle
000284769 3367_ $$2DataCite$$aOutput Types/Journal article
000284769 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1727267752_4397
000284769 3367_ $$2BibTeX$$aARTICLE
000284769 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000284769 3367_ $$00$$2EndNote$$aJournal Article
000284769 500__ $$a2024 Oct 1;154(4):688e-700e
000284769 520__ $$aThe driver of secondary lymphedema (SL) progression is chronic inflammation, which promotes fibrosis. Despite advances in preclinical research, a specific effector cell subpopulation as a biomarker for therapy response or stage progression is still missing for SL.Whole skin samples of 35 murine subjects of a microsurgical-induced SL model and 12 patients with SL were collected and their fibroblasts were isolated. These lymphedema-derived fibroblasts (LAF) were cultured in a collagen I-poly-D-Lysine 3D hydrogel to mimic skin conditions. Fibroblasts from non-lymphedema skin were used as negative control and TGF-β-stimulated fibroblasts were used to recreate profibrotic myofibroblasts. Quantitative immunocytofluorescence confocal microscopy analysis and invasion functional assays were performed in all subpopulations and statistically compared.In contrast to normal skin fibroblasts, LAF exhibit α-SMA-positive stress fibers and a reduced number of tight junctions in 3D hydrogel conditions. The switch from normal E-cadherin high phenotype to an N-cadherin high-E-cadherin low morphology suggests epithelial to mesenchymal transition for expansion and proliferation. This pathological behavior of LAF was confirmed by live cell imaging analysis of invasion assays. The significant activation of markers of the TGFBR2-Smad pathway and collagen synthesis (HSP-47) in LAF supports EMT phenotypic changes and previous findings relating to TGF-β1 and fibrosis with lymphedema.A characteristic SL myofibroblast subpopulation was identified and translationally related to fibrosis and TGF-β1-associated stage progression. This SL-related subpopulation was termed lymphedema-associated fibroblasts. A comprehensive stage-related characterization is required to validate LAF as a reliable biomarker for SL disease progression.
000284769 536__ $$0G:(DE-HGF)POF4-316$$a316 - Infektionen, Entzündung und Krebs (POF4-316)$$cPOF4-316$$fPOF IV$$x0
000284769 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000284769 7001_ $$aKilian, Katja$$b1
000284769 7001_ $$aBieback, Karen$$b2
000284769 7001_ $$0P:(DE-He78)df7cdd0583465c7f2056e3788bfefeec$$aFricke, Fabia$$b3
000284769 7001_ $$aBerner, Juan Enrique$$b4
000284769 7001_ $$aKneser, Ulrich$$b5
000284769 7001_ $$aHirche, Christoph$$b6
000284769 773__ $$0PERI:(DE-600)2037030-1$$a10.1097/PRS.0000000000011141$$n4$$p688e-700e$$tPlastic and reconstructive surgery$$v154$$x0032-1052$$y2024
000284769 909CO $$ooai:inrepo02.dkfz.de:284769$$pVDB
000284769 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)df7cdd0583465c7f2056e3788bfefeec$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000284769 9131_ $$0G:(DE-HGF)POF4-316$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vInfektionen, Entzündung und Krebs$$x0
000284769 9141_ $$y2023
000284769 915__ $$0LIC:(DE-HGF)CCBYNCNDNV$$2V:(DE-HGF)$$aCreative Commons Attribution-NonCommercial-NoDerivs CC BY-NC-ND (No Version)$$bDOAJ$$d2019-04-08T09:11:57Z
000284769 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2023-09-02
000284769 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2023-09-02
000284769 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2023-09-02
000284769 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2023-09-02
000284769 915__ $$0StatID:(DE-HGF)0410$$2StatID$$aAllianz-Lizenz$$d2023-08-26$$wger
000284769 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-08-26
000284769 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-08-26
000284769 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2023-08-26
000284769 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-08-26
000284769 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2023-08-26
000284769 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2023-08-26
000284769 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2023-08-26
000284769 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bPLAST RECONSTR SURG : 2022$$d2023-08-26
000284769 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-08-26
000284769 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2023-08-26
000284769 9201_ $$0I:(DE-He78)F210-20160331$$kF210$$lKKE Angewandte Tumorbiologie$$x0
000284769 980__ $$ajournal
000284769 980__ $$aVDB
000284769 980__ $$aI:(DE-He78)F210-20160331
000284769 980__ $$aUNRESTRICTED